Relative dose intensity (RDI) is a percentage that compares the chemotherapy dose you actually received to the dose that was originally planned. An RDI of 100% means you got every bit of chemotherapy at the full dose and on the exact schedule your oncologist intended. An RDI of 75% means you received only three-quarters of what was planned, whether because doses were lowered, treatments were delayed, or cycles were skipped entirely.
How RDI Is Calculated
The calculation has two steps. First, your care team determines something called “dose intensity,” which is the total amount of a drug delivered divided by the total time it took to deliver it. Think of it as how much chemotherapy your body received per week or per month. RDI then expresses that number as a percentage of what was recommended by the treatment protocol or evidence-based guidelines.
For example, if a standard regimen calls for 200 mg per week over 12 weeks, the planned dose intensity is 200 mg/week. If side effects forced a two-week delay and one dose reduction, your actual delivered dose intensity would be lower. Dividing your delivered number by the standard number and multiplying by 100 gives you your RDI.
Why the 85% Threshold Matters
Oncologists generally consider an RDI below 85% a clinically significant reduction. Some studies use 80% as the cutoff, but 85% is the more commonly referenced benchmark. Staying at or above that line is consistently linked to better survival across multiple cancer types.
A large meta-analysis published in The Oncologist pooled data from studies on breast, ovarian, lung, colorectal, and pancreatic cancers. For patients on platinum-based regimens (used in ovarian, lung, and breast cancers), those whose RDI fell below the 80-85% threshold had a 17% higher risk of death compared to patients who maintained their dose intensity. For patients on common colorectal and pancreatic cancer regimens, the gap was even wider: a 39% increased risk of death when RDI dropped below that same threshold.
In early breast cancer and aggressive lymphoma, where the goal of chemotherapy is often cure rather than disease control, the evidence is especially strong. Patients with lymphoma who receive full-dose chemotherapy consistently have better survival than those whose doses are reduced. For breast cancer, the survival benefit of maintaining RDI above roughly 85% has been demonstrated repeatedly in studies of regimens that include anthracyclines, one of the most commonly used classes of breast cancer drugs.
What Causes RDI to Drop
Three things lower your RDI: dose reductions (getting a smaller amount of the drug), dose delays (pushing a scheduled treatment back by days or weeks), and early discontinuation (stopping treatment before all planned cycles are complete). In practice, most of these changes happen because of side effects.
A study of women receiving chemotherapy for nonmetastatic breast cancer found that 38% experienced dose reductions. The most common reason was nerve damage in the hands and feet, which accounted for 36% of reductions. Low red blood cell counts caused another 9%, and low white blood cell counts (neutropenia) caused 8%. Sometimes the reason was simply unclear or multifactorial.
Older age and obesity are also associated with reduced RDI. Older patients tend to experience more severe side effects, and oncologists may preemptively lower doses out of caution, sometimes more than necessary. Obesity can complicate dosing calculations, leading some clinicians to cap doses below what body-surface-area formulas would call for.
How Care Teams Protect Your RDI
The most important tool for maintaining RDI is preventing the side effects that force dose changes in the first place. Neutropenia, the dangerous drop in infection-fighting white blood cells that chemotherapy commonly causes, is a major driver of both dose delays and reductions. To counter this, oncologists use growth factor injections (G-CSF) that stimulate the bone marrow to produce white blood cells faster. Clinical guidelines recommend G-CSF prophylaxis for regimens with a high risk of neutropenia, and studies confirm it improves the odds of maintaining a higher RDI.
Beyond growth factors, supportive care includes anti-nausea medications, blood transfusions or agents to address anemia, and close monitoring of blood counts between cycles so problems are caught before they force a delay. The overall strategy is straightforward: manage toxicities aggressively so that the treatment plan can stay on track.
What RDI Means for You as a Patient
If your oncologist mentions RDI, they’re tracking how closely your actual treatment matches the regimen that was tested in clinical trials and shown to work. The further you drift below the planned dose, the less certainty there is that you’re getting the full benefit. That doesn’t mean every dose reduction is harmful. Sometimes reducing a dose is the right call to keep you safe, and a small dip from 100% to 90% may have little practical impact. The concern is when cumulative delays and reductions push RDI well below 85%.
It’s worth asking your care team what your RDI is, especially if you’ve had treatments delayed or doses lowered more than once. Understanding this number gives you a clearer picture of whether your treatment is staying close enough to the original plan to remain effective, and whether additional supportive care might help you tolerate the full regimen.